Table of Contents
Share At:
Listen Article:
0:00 /
0:00
Fulvestrant Injection for Breast Cancer Treatment
Table of Contents
What are the Precautions for Administering Fulvestrant?
Whether you are a doctor or patient, a number of precautions for administering fulvestrant injection should be considered. Fulvestrant is a medication that belongs to a group of drugs called estrogen receptor antagonists. It is used in the treatment of hormone receptor-positive advanced breast cancer.
Fulvestrant is given intramuscularly and usually given once a month. However, it may be given as often as every month.
How Should Fulvestrant Injection be Administered?
Fulvestrant (also known as Faslodex) is a hormone used in cancer treatment. It is a competitive estrogen receptor (ER) antagonist. Fulvestrant is used in combination with targeted cancer drugs. Fulvestrant blocks the estrogen receptor to slow the growth of some breast cancer cells. Fulvestrant is given intravenously or intramuscularly. Fulvestrant is one of the most tolerable endocrine therapies available.
Fulvestrant is administered in cycles of 28 days. Each cycle consists of two injections into the buttock, one on day one and the other on day 15. Fulvestrant is available in 10 ng/mL.
Fulvestrant is a selective estrogen receptor downregulator (SERD). Fulvestrant is an antiestrogen that is used in combination with palbociclib to treat hormone receptor positive advanced breast cancer. It is administered as two separate injections. The first is administered intramuscularly and the second is administered intradermally.
What are the Effects of Fulvestrant on Fertility?
Fulvestrant has been shown to have a number of negative effects on fertility in female rats. It has been associated with increased post-implantation loss, and decreased fertility. It has been recommended that women using this drug should use effective contraception during treatment and for at least one year after the last dose.
Fulvestrant is a selective oestrogen receptor antagonist (SERA), which blocks oestrogen receptors on cancer cells. Fulvestrant has a wide distribution and a high 99% plasma protein binding. It is given as an injection into muscle in the buttock.
Effects of Fulvestrant on Uterotrophic Action of Estradiol
fulvestrant is a 7a-alkylsulphinyl analogue of 17b-oestradiol which inhibits uterotrophic action of estradiol. It also blocks oestrogen-regulated genes. In some breast cancer models, fulvestrant has antitumour activity.
It has been reported that fulvestrant is metabolized by CYP 3A4. It is not known whether fulvestrant is excreted in human milk. fulvestrant is given as an intramuscular injection to patients. It is given in cycles of 28 days with injections on days 1 and 15. Fulvestrant has a 40-day half-life. It is excreted by the hepatobiliary route. It has been found to inhibit the growth of the Br10 human tumor model. In addition, fulvestrant inhibits oestrogen-stimulated thickening of the endometrium and ER-mediated transcriptional activity.
The Bottom Line
Fulvestrant is a molecule that is metabolized by a variety of biotransformation pathways. Its metabolism involves oxidation of side chain sulphoxide, conjugation with glucuronic acid and aromatic hydroxylation. The metabolized form of fulvestrant is rapidly cleared by the hepatobiliary route.
